Search clinical trials for: Valsartan 160mg

Total 1919 results

Klinikum Nürnberg

Recruiting

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. (DapaBalci-Leap)

Chronic Renal Failure | Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis

Germany, France
Newcastle-upon-Tyne Hospitals NHS Trust
Assistance Publique - Hôpitaux de Paris; Azienda Ospedaliero-Universitaria... and other collaborators

Completed

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

United Kingdom
Novartis Pharmaceuticals

Completed

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Heart Failure

United States
Clinision

Completed

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

Heart Failure NYHA Class II | Heart Failure NYHA Class IV

Pakistan
Erasmus Medical Center

Completed

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA)

Colorectal Neoplasms | Gastrointestinal Stromal Tumors

Netherlands
GlaxoSmithKline

Completed

Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

Rhinitis, Allergic, Seasonal

Germany
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
University of Zagreb

Active, not recruiting

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients (ENVAD-HF)

Heart Failure

Netherlands, Croatia, Poland, Czechia
Torbjorn Omland
Oslo University Hospital; Novartis; University Hospital of North Norway; Helse... and other collaborators

Active, not recruiting

Prevention of Cardiac Dysfunction During Breast Cancer Therapy (PRADAII)

Heart Failure | Breast Cancer Female

Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE)

Chronic Heart Failure (CHF)

Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
Ziekenhuis Oost-Limburg
Jessa Hospital

Recruiting

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation (PRAISE-MR)

Heart Failure With Preserved Ejection Fraction | Functional Mitral Regurgitation

Belgium
Shenzhen Second People's Hospital

Recruiting

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Heart Failure | Hemodialysis Complication | Peritoneal Dialysis Complication

China
Horng Chen

Enrolling by invitation

Enhancing the Natriuretic Peptide System in HFpEF

Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Germans Trias i Pujol Hospital

Completed

Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device (ARNIMEMS-HFpEF)

Pulmonary Hypertension

Spain
University Hospital, Montpellier

Completed

Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study (ENTRESTO696)

Chronic Heart Failure | Sleep Apnea Syndrome

France
Novartis Pharmaceuticals

Completed

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. (AWAKE-HF)

Heart Failure, Reduced Ejection Fraction

United States
Sun Yat-sen University

Completed

Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Renal Function Disorder

China
Radboud University Medical Center
Astellas Pharma Europe B.V.

Completed

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE)

Metastatic Castration Resistant Prostate Cancer

Netherlands
NYU Langone Health

Terminated

A mGlu2/3 Agonist in the Treatment of PTSD

Post-traumatic Stress Disorder
Novartis

Completed

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Proteinuria | Microalbuminuria

Egypt
Novartis

Completed

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Diastolic Dysfunction, Symptomatic Heart Failure

Switzerland, Germany
Kumamoto University

Terminated

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Hypertension

Japan
Novartis

Completed

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Hypertension

Germany
Novartis

Completed

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Hypertension

Switzerland
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
HK inno.N Corporation

Completed

Bioequivalence Study of CJ-30061 in Healthy Male Volunteers

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis Pharmaceuticals

Completed

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. (PIONEER-HF)

Acute Heart Failure

United States
Samsung Medical Center

Unknown

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
National Heart Centre Singapore
National Medical Research Council (NMRC), Singapore

Recruiting

Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH)

Hypertensive Heart Disease

Singapore
Newcastle University
University of Belgrade; Azienda Ospedaliero-Universitaria Careggi; University... and other collaborators

Completed

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

Germany, Italy, Serbia, United Kingdom
National Institute of Cardiovascular Diseases,...

Completed

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Heart Failure, Systolic

Pakistan
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Wake Forest University Health Sciences
Johns Hopkins University

Terminated

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients (RAS-HIV)

HIV | Sarcopenia | Aging | Angiotensin Receptor Antagonists

United States
The Affiliated Hospital of Qingdao University

Recruiting

Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

Cardio-Renal Syndrome

China
Montreal Heart Institute
Novartis Pharmaceuticals

Terminated

ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure (PARACYS-RV)

Heart Failure | Systemic Right Ventricle

Canada
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Instituto de Investigacion Sanitaria La Fe

Completed

Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Epilepsy

Spain
Massachusetts General Hospital

Recruiting

Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)

HIV/AIDS | Heart Failure With Preserved Ejection Fraction

United States
Novartis Pharmaceuticals

Completed

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF)

Chronic Heart Failure With Reduced Ejection Fraction

Belgium, Estonia, Denmark, Greece, United Kingdom, Germany, Latvia, Lithuania, Spain, Netherlands, Bulgaria, Finland, Poland, Czechia, Iceland, Sweden, France, Ireland, Norway
Novartis Pharmaceuticals

Completed

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Hypertension | Chronic Kidney Disease | Nephrotic Syndrome

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Hypertension

United States
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519

Healthy Volunteers

Korea, Republic of
Dr. Reddy's Laboratories (Thailand) Limited

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Healthy Volunteers

Thailand

3

Subscribe